Strontium ranelate and vertebral fractures
In a three-year trial in 1,649 postmenopausal women with osteoporosis, oral strontium ranelate reduced the risk of new vertebral fractures by 41% and raised lumbar-spine bone density by 14.4%.
As reported in: Meunier, Roux, Seeman et al. (2004). The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis. New England Journal of Medicine. doi:10.1056/nejmoa022436